Tags

Type your tag names separated by a space and hit enter

Soybean phenolic-rich extracts inhibit key-enzymes linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (angiotensin I converting enzyme) in vitro.
Exp Toxicol Pathol. 2013 Mar; 65(3):305-9.ET

Abstract

This study sought to assess the inhibitory activities of phenolic-rich extracts from soybean on α-amylase, α-glucosidase and angiotensin I converting enzyme (ACE) activities in vitro. The free phenolic extract of the soybean was obtained by extraction with 80% acetone, while that of the bound phenolic extract was done by extracting the alkaline and acid hydrolyzed residue with ethyl acetate. The inhibitory action of these extracts on the enzymes activity as well as their antioxidant properties was assessed. Both phenolic-rich extracts inhibited α-amylase, α-glucosidase and ACE enzyme activities in a dose dependent pattern. However, the bound phenolic extract exhibited significantly (P < 0.05) higher α-amylase and ACE inhibition while the free phenolic extract had significantly (P < 0.05) higher α-glucosidase inhibitory activity. Nevertheless, the free phenolic extract had higher α-glucosidase inhibitory activity when compared to that of α-amylase; this property confer an advantage on soybean phenolic-rich extracts over commercial antidiabetic drugs with little or no side effect. And inhibition of ACE suggests the antihypertension potential of soybean phenolic-rich extracts. Furthermore, the enzyme inhibitory activities of the phenolic-rich extracts were not associated with their phenolic content. Therefore, phenolic-rich extracts of soybean could inhibit key-enzyme linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (ACE) and thus could explain in part the mechanism by which soybean renders these health promoting effect.

Links

Publisher Full Text

Authors+Show Affiliations

Ademiluyi AO
Department of Biochemistry, Federal University of Technology, Akure, P.M.B. 704, Akure 340001, Nigeria.
Oboh G
No affiliation info available

MeSH

Angiotensin-Converting Enzyme InhibitorsAntioxidantsDiabetes Mellitus, Type 2Dose-Response Relationship, DrugEnzyme InhibitorsGlycoside Hydrolase InhibitorsHypertensionPeptidyl-Dipeptidase APhenolsPlant ExtractsSoybeansalpha-Amylases

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22005499

Citation

Ademiluyi, Adedayo O., and Ganiyu Oboh. "Soybean Phenolic-rich Extracts Inhibit Key-enzymes Linked to Type 2 Diabetes (α-amylase and Α-glucosidase) and Hypertension (angiotensin I Converting Enzyme) in Vitro." Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie, vol. 65, no. 3, 2013, pp. 305-9.
Ademiluyi AO, Oboh G. Soybean phenolic-rich extracts inhibit key-enzymes linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (angiotensin I converting enzyme) in vitro. Exp Toxicol Pathol. 2013;65(3):305-9.
Ademiluyi, A. O., & Oboh, G. (2013). Soybean phenolic-rich extracts inhibit key-enzymes linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (angiotensin I converting enzyme) in vitro. Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie, 65(3), 305-9. https://doi.org/10.1016/j.etp.2011.09.005
Ademiluyi AO, Oboh G. Soybean Phenolic-rich Extracts Inhibit Key-enzymes Linked to Type 2 Diabetes (α-amylase and Α-glucosidase) and Hypertension (angiotensin I Converting Enzyme) in Vitro. Exp Toxicol Pathol. 2013;65(3):305-9. PubMed PMID: 22005499.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soybean phenolic-rich extracts inhibit key-enzymes linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (angiotensin I converting enzyme) in vitro. AU - Ademiluyi,Adedayo O, AU - Oboh,Ganiyu, Y1 - 2011/10/17/ PY - 2010/05/17/received PY - 2011/07/14/revised PY - 2011/09/25/accepted PY - 2011/10/19/entrez PY - 2011/10/19/pubmed PY - 2013/7/13/medline SP - 305 EP - 9 JF - Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie JO - Exp Toxicol Pathol VL - 65 IS - 3 N2 - This study sought to assess the inhibitory activities of phenolic-rich extracts from soybean on α-amylase, α-glucosidase and angiotensin I converting enzyme (ACE) activities in vitro. The free phenolic extract of the soybean was obtained by extraction with 80% acetone, while that of the bound phenolic extract was done by extracting the alkaline and acid hydrolyzed residue with ethyl acetate. The inhibitory action of these extracts on the enzymes activity as well as their antioxidant properties was assessed. Both phenolic-rich extracts inhibited α-amylase, α-glucosidase and ACE enzyme activities in a dose dependent pattern. However, the bound phenolic extract exhibited significantly (P < 0.05) higher α-amylase and ACE inhibition while the free phenolic extract had significantly (P < 0.05) higher α-glucosidase inhibitory activity. Nevertheless, the free phenolic extract had higher α-glucosidase inhibitory activity when compared to that of α-amylase; this property confer an advantage on soybean phenolic-rich extracts over commercial antidiabetic drugs with little or no side effect. And inhibition of ACE suggests the antihypertension potential of soybean phenolic-rich extracts. Furthermore, the enzyme inhibitory activities of the phenolic-rich extracts were not associated with their phenolic content. Therefore, phenolic-rich extracts of soybean could inhibit key-enzyme linked to type 2 diabetes (α-amylase and α-glucosidase) and hypertension (ACE) and thus could explain in part the mechanism by which soybean renders these health promoting effect. SN - 1618-1433 UR - https://www.unboundmedicine.com/medline/citation/22005499/Soybean_phenolic_rich_extracts_inhibit_key_enzymes_linked_to_type_2_diabetes__α_amylase_and_α_glucosidase__and_hypertension__angiotensin_I_converting_enzyme__in_vitro_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0940-2993(11)00143-6 DB - PRIME DP - Unbound Medicine ER -